Historical mdt News Stories
Medtronic Catalysts: FDA Wins, Spin-Off Momentum24
Recent FDA clearances for Medtronic's Stealth AXiS system and expanded OmniaSecure lead indication, combined with the MiniMed Group IPO timeline and improving EBITDA, create tangible catalysts for MDT stock and investor sentiment.
Medtronic Shift: MiniMed IPO, Robotics & Liability
Medtronic's recent MiniMed IPO, FDA clearances for new robotic spine and surgical platforms, and a Supreme Court ruling narrowing liability for FDA-approved devices together reshape MDT's risk profile and strategic focus. These concrete events can materially influence investor valuation and capital allocation.
Medtronic Q3 Gains, Diabetes Spin-Off Uncertainty.
Medtronic reported a solid Q3 with revenue growth, key device approvals and strong cardiac ablation performance, but investor enthusiasm was tempered by a planned Diabetes spin-off and tariff-driven margin pressure.
Medtronic's MiniMed IPO Sparks Q3 Growth Surge
Medtronic’s MiniMed IPO plans and a strong Q3 performance — led by Pulsed Field Ablation and robotics — have reinvigorated investor interest in MDT. Near-term upside is balanced by tariff headwinds and execution risk as the company navigates a multi-product launch cycle.
Medtronic Hit by $382M Verdict; Catalysts Ahead Q1
Medtronic (MDT) faced a $382M antitrust verdict this week that pressures near-term results, while strategic moves—an acquisition of CathWorks, diabetes device approvals and Medicare coverage—reinforce long-term growth pathways. Mixed Q3 results, tariff exposure and cautious guidance kept investor sentiment muted despite an analyst upgrade.
Medtronic Q3 Beat, Guidance Leaves Investors Cold.
Medtronic reported a modest Q3 beat in revenue and adjusted EPS but kept full-year guidance unchanged. Tariff-related costs and cautious outlook pressured MDT shares, with elevated trading volume suggesting institutional repositioning.
Medtronic Catalysts: CathWorks Buy, Diabetes Wins!
Medtronic (MDT) saw near‑term share pressure even as the company secured regulatory wins for its MiniMed 780G insulin platform and moved toward acquiring CathWorks, an AI cardiac-imaging firm. Recent analyst upgrades, Medicare coverage, and product clearances create tangible growth catalysts for the diabetes and cardiology franchises.